Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Plasma concentrations of direct oral anticoagulants (DOAC) are potentially affected because of drug-drug interactions (DDI) with anticancer treatment as a result of inhibition or induction of CYP3A4, p-glycoprotein (P-gp) and/or Breast Cancer Resistance Protein (BCRP) interactions.Here, we present a...

Full description

Bibliographic Details
Main Authors: J.L. Gulikers, M. Slikkerveer, K. Winckers, L.E.L. Hendriks, S. Dursun, S. Croes, R.M.J.M. van Geel
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Apixaban
Alectinib
DOAC
DDI
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000503

Internet

http://www.sciencedirect.com/science/article/pii/S2666621922000503

Similar Items